HE4及Vimentin在子宫内膜癌中的研究进展

Research Progress of HE4 and Vimentin in Endometrial Carcinoma

子宫内膜癌(Endometrial Cancer, EC)是常见的妇科恶性肿瘤之一,其发病率随着时间的推移而增加,严重威胁妇女的健康与生存。大多数女性以绝经后阴道不规则出血为主要症状。以往,在临床实践中,有症状的妇女通过包括经阴道镜、子宫内膜活检和宫腔镜在内的检查进行诊断。近年来,多项研究证明血清肿瘤标志物以及组织免疫组化标记物在协助EC诊断及监测预后等方面都有重要临床意义。经国内外多项研究证明,血清肿瘤标记物血清人附睾蛋白4 (HE4)水平升高及组织免疫组化标记物波形蛋白(Vimentin, Vim)阳性表达率升高与子宫内膜癌诊断及预后有关。本文旨在讨论术前血清肿瘤标记物HE4联合术后组织免疫组化标记物Vim与子宫内膜癌的分期和病理特征(组织学类型、组织学分级、手术病理分期、肌层浸润深度、淋巴结转移及预后)的相关性,致力于形成可靠的诊疗和预后判断,让妇科医生更好地适应手术分期和辅助治疗,改善子宫内膜癌患者的预后或生活质量。

Endometrial Cancer (EC) is one of the common gynecological malignancies. Its incidence increases with time, which seriously threatens women’s health and survival. In most women, irregular vaginal bleeding after menopause is the main symptom. Historically, in clinical practice, symptomatic women were diagnosed by tests including transcolposcopy, endometrial biopsy, and hysteroscopy. In recent years, a number of studies have demonstrated that serum tumor markers and tissue im-munohistochemical markers have important clinical significance in assisting EC diagnosis and mon-itoring prognosis. A number of studies at home and abroad have proved that the increased level of serum tumor marker human epididymal protein 4 (HE4) and the increased positive expression rate of tissue immunohistochemical marker Vimentin (Vim) are associated with the diagnosis and prog-nosis of endometrial cancer. This paper aims to discuss the correlation between preoperative serum tumor marker HE4 combined with postoperative tissue immunohistochemical marker Vim and the staging and pathological features of endometrial cancer (histological type, histological grade, surgi-cal pathological stage, depth of muscular infiltration, lymph node metastasis and prognosis), so as to form reliable diagnosis, treatment and prognosis, to better adapt gynecologists to surgical staging and adjuvant therapy, improve the prognosis or quality of life of patients with endometrial cancer.